More reads

• Jacobus prices its rare disease drug at half of what Catalyst charges, but will doctors prescribe it? (STAT Plus)
• Russian biologist plans more CRISPR-edited babies. (Nature)
• A fallen star: Death knell sounds for Neil Woodford. (Financial News)
• Diabetes-coaching startup’s expected IPO will offer a test of the health tech sector’s prospects. (STAT Plus)